Neurol. pro Praxi, 2001; 4: 179-183

Trombolýza mozkového infarktu

MUDr. Robert Mikulík1, MUDr. Michal Dufek2
1 I. neurologická klinika LF MU a FN u sv. Anny Brno
2 Cerebrovaskulární centrum, Neurologická klinika, Fakultní nemocnice u sv. Anny, Brno

Keywords: trombolýza, tPA, tkáňový aktivátor plazminogenu, terapie iktu.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mikulík R, Dufek M. Trombolýza mozkového infarktu. Neurol. praxi. 2001;2(4):179-183.

Princip trombolytické terapie spočívá v rekanalizaci tepny uzavřené trombem nebo embolem. Trombolytická terapie je jedinou dosud prokázaně účinnou léčbou mozkového infarktu. K léčbě používáme tkáňový aktivátor plazminogenu aplikovaný do 3 hodin od počátku příznaku. Hlavními nevýhodami této léčby je velmi úzké terapeutické časové okno a riziko intracerebrálního krvácení. Na neurologické klinice FN u sv. Anny v Brně jsme od založení trombolytického programu v roce 1998 do července roku 2001 trombolyzovali celkem 31 pacientů. Dosáhli jsme stejně dobrých výsledků jako ve studii NINDS.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams, H. P., Brott, T. G., Furlan, A. J., et al (1996). Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 27, 1711-1718. Go to original source... Go to PubMed...
    2. Brott, T. G., Haley, E. C. Jr, Levy, D. E., Barsan, W., Broderick, J., Sheppard, G. L., et al (1992). Urgent therapy for stroke. Part I: pilot study of tissue plasminogen activator admininstered within 90 minutes. Stroke, 23: 632-640. Go to original source... Go to PubMed...
    3. Donnan, G. A., Davis, S. M., Chambers, B. R., Gates, P. C., Hankey, G. J., McNeil, J. J., et al (1995). Trials of streptokinase in severe acute ischaemic stroke. Lancet, 345: 578-579. Go to original source...
    4. Fieschi, C., Argentino, C., Lenzi, G. L., Sacchetti, M. L., Toni, D., Bozzao, L. (1989). Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neuro Sci, 91: 311-322. Go to original source... Go to PubMed...
    5. Furlan, A. J., Higashida, R., Wechsler, L., Gent, M., Rowley, H., Kase, C., et al (1999). Intra-arterial Prourokinase for Acute Ischemic Stroke: the PROACT II Study: A Randomized Controlled Trial. JAMA, 282: 2003-2001. Go to original source... Go to PubMed...
    6. Grond, M., Stenzel, Ch., Schmulling, S., Rudolf, J., Neveling, M., Lechleuthner, A., et al. (1998). Early Intravenous Thrombolysis for Acute Ischemic Stroke in a Community-Based Approach. Stroke, 29: 1544-1549. Go to original source... Go to PubMed...
    7. Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., et al. (1995): Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA, 274: 1017-1025. Go to original source... Go to PubMed...
    8. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., at al (1998): for the Second European-Australian Acute Stroke Study Investigator: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet, 352: 1245-1251. Go to original source... Go to PubMed...
    9. Haley, E. C., Broth, T. C., Sheapard, G. L., Barsan, W., Broderick, J., Marler, J. R., et al (1993): Pilot Randomized Trial of Tissue Plasminogen Activator in Acute Ischemic Stroke. The TPA Bridging Study. Stroke, 24: 1000-1004. Go to original source... Go to PubMed...
    10. Haley, Jr E. C., Levy, D. E., Brott, T. G,, Sheppard, G. L., Wong, M. C. W., Kongable GL, et al (1992): Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke, 23: 641-645. Go to original source... Go to PubMed...
    11. Hommel, M., Boissel, J. P., Cornu, C., Boutitie, F., Less, K. R,, Besson, G., et al. for the MAST Study Group (1994): Termintion of trial of streptokinase in severe acute ischaemic stroke. Lancet., 345: 57. Letter. Go to original source... Go to PubMed...
    12. Chiu, D., Krieger, D., Villar-Cordova, C. (1998): Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Feasebility, Safety, and Efficacy in the First Year of Clinical Practise. Stroke, 29: 18-22. Go to original source... Go to PubMed...
    13. Kalafut, M., Jeffrey, L. Saver. (2001): 53RD Annual meeting of the American Academy of Neurology, Medscape.
    14. Multicentre Acute Stroke Trial-Italy (MAST-I) Group (1995): Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet, 346: 1509-1514. Go to original source...
    15. The National Institute of Neurological Disorders and Stroke (NINDS) tPA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke (1995). N Engl J Med, 333: 1581-1587. Go to original source... Go to PubMed...
    16. NINDS tPA Stroke Study Group (1997): Tissue plasminogen activator for Acute Stroke. Stroke, 28: 2119-2125. Go to original source... Go to PubMed...
    17. Thrombolysis-Karolinska Stroke Update Consensus Statement 2000 (2000). 3rd Karolinska Stroke Update meeting.
    18. del Zoppo, G. J., Higashida, R. T., Furlan, A. J., Pessin, M. S., Rowley, H. A., Gent, M., et al. (1998): PROACT: a phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke, 29: 4-11. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.